Suppr超能文献

用于评估mRNA新冠病毒疫苗免疫后细胞免疫的新冠病毒定量干扰素检测:一项系统评价和荟萃分析

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis.

作者信息

Dourdouna Maria-Myrto, Kourlaba Georgia, Michos Athanasios

机构信息

Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, Aghia Sophia" Children's Hospital, 11527, Athens, Greece.

Department of Nursing, University of Peloponnese, Tripoli, Greece.

出版信息

Immunol Res. 2024 Dec 27;73(1):25. doi: 10.1007/s12026-024-09570-w.

Abstract

A systematic review and meta-analysis were performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON SARS-CoV-2 interferon-γ release assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS, and medRxiv databases, to identify studies reporting the QuantiFERON SARS-CoV-2 (Starter (two antigen tubes) or Starter + Extended Pack (three antigen tubes), cut-off ≥ 0.15 IU/mL) positivity rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses. Study quality was evaluated with the Critical Appraisal Skills Programme Tool. A meta-analysis was conducted using a random-effects model. Heterogeneity and publication bias were assessed. Eleven eligible studies (with 5-73 vaccinated immunocompetent participants) were identified. For COVID-19-naïve participants, ≤ 3 months after the second dose, the pooled PR (random-effects model) was 86 (95% confidence interval (95% CI) 78-95%). Comparing the Starter vs. the Starter + Extended Pack, a significant difference in PRs was detected (80.6% vs. 100% p-value < 0.001). At 3-6 and >6 months after the second dose and ≥ 3 months after the third dose, the pooled PRs were 59% (95% CI 45-72%), 79% (95% CI 66-92%), and 66% (95% CI 50-82%), respectively. For convalescent participants, ≥ 6 months after the third dose, the pooled PR was 81% (95% CI 67-95%). Limitations include heterogeneity and a small number of studies, at some timepoints. In conclusion, following the second or third COVID-19 mRNA vaccine dose, QuantiFERON SARS-CoV-2 detected positive responses in a certain percentage of the vaccinees, possibly because of waning immunity, reduced assay sensitivity, or lack of T-cell response induction in some vaccinees. The detection of positive responses was higher when the Starter + Extended Pack was used. PROSPERO Registration Number: CRD42023431315.

摘要

使用定量干扰素γ释放试验(QuantiFERON SARS-CoV-2)进行了一项系统评价和荟萃分析,以评估新型冠状病毒肺炎(COVID-19)信使核糖核酸(mRNA)疫苗接种后的病毒特异性T细胞反应。于2023年6月8日在PubMed、Scopus和medRxiv数据库中进行检索,以确定报告在免疫功能正常的成年人中接种两剂或三剂COVID-19 mRNA疫苗后,定量干扰素γ释放试验(QuantiFERON SARS-CoV-2)(起始剂(两个抗原管)或起始剂+扩展包(三个抗原管),临界值≥0.15 IU/mL)阳性率(PR)的研究。使用批判性评估技能计划工具对研究质量进行评估。采用随机效应模型进行荟萃分析。评估了异质性和发表偏倚。确定了11项符合条件的研究(有5-73名接种疫苗的免疫功能正常参与者)。对于未感染COVID-19的参与者,在第二剂疫苗接种后≤3个月,合并阳性率(随机效应模型)为86%(95%置信区间(95%CI)78%-95%)。比较起始剂与起始剂+扩展包,检测到阳性率有显著差异(80.6%对100%,P值<0.001)。在第二剂疫苗接种后3-6个月和>6个月以及第三剂疫苗接种后≥3个月,合并阳性率分别为59%(95%CI 45%-72%)、79%(95%CI 66%-92%)和66%(95%CI 50%-82%)。对于康复期参与者,在第三剂疫苗接种后≥6个月,合并阳性率为81%(95%CI 67%-95%)。局限性包括异质性以及在某些时间点研究数量较少。总之,在接种第二剂或第三剂COVID-19 mRNA疫苗后,定量干扰素γ释放试验(QuantiFERON SARS-CoV-2)在一定比例的疫苗接种者中检测到阳性反应,这可能是由于免疫力下降、检测灵敏度降低或一些疫苗接种者缺乏T细胞反应诱导。使用起始剂+扩展包时阳性反应的检测率更高。国际前瞻性系统评价注册库(PROSPERO)注册号:CRD42023431315。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验